These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 20147323

  • 21. Antimicrobial activity of fosfomycin against multidrug-resistant Pseudomonas aeruginosa in vitro.
    Kobayashi Y, Sumitani Y, Sugita K, Aikawa N.
    Int J Antimicrob Agents; 2007 Dec; 30(6):563-4. PubMed ID: 17900870
    [No Abstract] [Full Text] [Related]

  • 22. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients.
    Johnson LE, D'Agata EM, Paterson DL, Clarke L, Qureshi ZA, Potoski BA, Peleg AY.
    Transpl Infect Dis; 2009 Jun; 11(3):227-34. PubMed ID: 19302282
    [Abstract] [Full Text] [Related]

  • 23. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology.
    Tacconelli E, Tumbarello M, Bertagnolio S, Citton R, Spanu T, Fadda G, Cauda R.
    Emerg Infect Dis; 2002 Feb; 8(2):220-1. PubMed ID: 11897080
    [No Abstract] [Full Text] [Related]

  • 24. Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors.
    Trinh TD, Zasowski EJ, Claeys KC, Lagnf AM, Kidambi S, Davis SL, Rybak MJ.
    Diagn Microbiol Infect Dis; 2017 Sep; 89(1):61-66. PubMed ID: 28716451
    [Abstract] [Full Text] [Related]

  • 25. Pseudomonas aeruginosa bacteraemia in burns patients: Risk factors and outcomes.
    Mahar P, Padiglione AA, Cleland H, Paul E, Hinrichs M, Wasiak J.
    Burns; 2010 Dec; 36(8):1228-33. PubMed ID: 20965109
    [Abstract] [Full Text] [Related]

  • 26. An outbreak of imipenem-resistant Pseudomonas aeruginosa in an intensive care unit.
    Majumdar S, Kirby A, Berry N, Williams C, Hassan I, Eddleston J, Burnie JP.
    J Hosp Infect; 2004 Oct; 58(2):160-1. PubMed ID: 15474190
    [No Abstract] [Full Text] [Related]

  • 27. Surveillance of antimicrobial susceptibility of Pseudomonas aeruginosa clinical isolates from a central hospital in Portugal.
    Cardoso O, Alves AF, Leitão R.
    J Antimicrob Chemother; 2007 Aug; 60(2):452-4. PubMed ID: 17576698
    [No Abstract] [Full Text] [Related]

  • 28. Ventilator-associated pneumonia caused by Pseudomonas infection.
    Dunn M, Wunderink RG.
    Clin Chest Med; 1995 Mar; 16(1):95-109. PubMed ID: 7768096
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Five-year report of national surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolated from non-tertiary care hospitals in Korea (2002-2006).
    Yoo J, Sohn ES, Chung GT, Lee EH, Lee KR, Park YK, Lee YS.
    Diagn Microbiol Infect Dis; 2008 Mar; 60(3):291-4. PubMed ID: 18068936
    [Abstract] [Full Text] [Related]

  • 32. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
    Kwa AL, Loh C, Low JG, Kurup A, Tam VH.
    Clin Infect Dis; 2005 Sep 01; 41(5):754-7. PubMed ID: 16080101
    [Abstract] [Full Text] [Related]

  • 33. Risk factors for health care-associated pneumonia: transmission of multidrug-resistant Pseudomonas aeruginosa isolates from general hospitals to nursing homes.
    Fujimura S, Nakano Y, Takane H, Kikuchi T, Watanabe A.
    Am J Infect Control; 2011 Mar 01; 39(2):173-5. PubMed ID: 21356435
    [No Abstract] [Full Text] [Related]

  • 34. [Monitoring of antibiotic resistance in Ps. aeruginosa and in Ps. maltophilia in the Ospedale di Pordenone].
    Chiaradia V, Santini GF.
    G Ital Chemioter; 1988 Mar 01; 35(1-3):23-5. PubMed ID: 3151487
    [No Abstract] [Full Text] [Related]

  • 35. [Pyocyanea infections and sensitivity to antibiotics].
    Kamoun A, Ben Hassen E, Ben Redjeb S.
    Tunis Med; 1990 Apr 01; 68(4):275-9. PubMed ID: 2112795
    [No Abstract] [Full Text] [Related]

  • 36. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.
    Rossolini GM, Mantengoli E.
    Clin Microbiol Infect; 2005 Jul 01; 11 Suppl 4():17-32. PubMed ID: 15953020
    [Abstract] [Full Text] [Related]

  • 37. [Is the quantitative antibiogram a reliable epidemiological marker for Pseudomonas aeruginosa infections? Comparison with pulsed field electrophoresis].
    Foissaud V, Perrier-Gros-Claude JD, Rouby Y, Clavier B, Dusseau JY, Thierry J.
    Pathol Biol (Paris); 1998 Jun 01; 46(6):452-8. PubMed ID: 9769881
    [Abstract] [Full Text] [Related]

  • 38. Current therapies for pseudomonas aeruginosa.
    Giamarellou H, Kanellakopoulou K.
    Crit Care Clin; 2008 Apr 01; 24(2):261-78, viii. PubMed ID: 18361945
    [Abstract] [Full Text] [Related]

  • 39. [Role of Pseudomonas aeruginosa in the etiology of infectious complications in cancer patients].
    Smolianskaia AZ, Sakaian NN, Grinenko GI, Anan'ev VS, Dronova OM.
    Vopr Onkol; 1986 Apr 01; 32(12):33-7. PubMed ID: 3099468
    [Abstract] [Full Text] [Related]

  • 40. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections.
    Cao B, Wang H, Sun H, Zhu Y, Chen M.
    J Hosp Infect; 2004 Jun 01; 57(2):112-8. PubMed ID: 15183240
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.